In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...

Navigating the challenges of conducting clinical trials for Metabolic Associated Steatohepatitis (MASH), a liver disease commonly associated with Non-Alcoholic Fatty Liver Disease (NAFLD). Learn ...

Methods and analysis This trial is a randomised, double-blind, placebo-controlled study investigating the therapeutic potential of lyophilised faecal microbiota capsules (LFMCs) in individuals with ...

These organizations can help you educate yourself, spread awareness, and connect with the MASH community to help you better manage your health.

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Objective Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine ...